CHChang He

Chang He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chang He has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Bingde Yin

    Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai, 201199, China

    1 shared publication
  • Dongzhen Jiang

    Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai, 201199, China

    1 shared publication
  • Fan Yang

    Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai 201199, China

    1 shared publication
  • Fan Yang

    Department of Urology

    1 shared publication
  • Huawei Zhang

    Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai, 201199, China

    1 shared publication
  • Jiawen Wu

    Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai 201199, China

    1 shared publication

Latest Publications

  • The Prognostic Hub Gene POLE2 Promotes BLCA Cell Growth via the PI3K/AKT Signaling Pathway

    by Dongzhen Jiang, Huawei Zhang, Bingde Yin, Minke He, Xuwei Lu, Chang He

    Background:: BLCA is a common urothelial malignancy characterized by a high recurrence rate. Despite its prevalence, the molecular mechanisms underlying its development remain unclear.Aims:: This study aimed to explore new prognostic biomarkers and investigate the underlying mechanism of bladder cancer (BLCA).Objective:: The objective of this study is to identify key prognostic biomarkers for BLCA and to elucidate their roles in the disease.Methods:: We first collected the overlapping DEGs from GSE42089 and TCGA-BLCA samples for the subsequent weighted gene co-expression network analysis (WGCNA) to find a key module. Then, key module genes were analyzed by the MCODE algorithm, prognostic risk model, expression and immunohistochemical staining to identify the prognostic hub gene. Finally, the hub gene was subjected to clinical feature analysis, as well as cellular function assays.Results:: In WGCNA on 1037 overlapping genes, the blue module was the key module. After a series of bioinformatics analyses, POLE2 was identified as a prognostic hub gene in BLCA from potential genes (TROAP, POLE2, ANLN, and E2F8). POLE2 level was increased in BLCA and related to different clinical features of BLCA patients. Cellular assays showed that si-POLE2 inhibited BLCA proliferation, and si-POLE2+ 740Y-P in BLCA cells up-regulated the PI3K and AKT protein levels.Conclusion:: In conclusion, POLE2 was identified to be a promising prognostic biomarker as an oncogene in BLCA. It was also found that POLE2 exerts a promoting function by the PI3K/AKT signaling pathway in BLCA.


  • Open Access

    Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer

    by Ning Yang, Jiawen Wu, Tiancheng Zhang, Fan Yang, Jinyan Shao, Chang He, Liang Qin

    Objective. Prostate cancer (PCa) is considered the most serious cancer in the world. Nevertheless, the accuracy of current biomarkers, such as pathological staging, Gleasons score, and serum prostate-specific antigen (PSA) levels, is limited. FOXO1 is a key downstream effector of PTEN and a tumor suppressor in PCA, which has been reported extensively. However, the clinical relevance of FOXO1 in PCa remains unclear. Methods. In this study, we first detected its expression in four public databases to explore the clinical role of FOXO1. Verification of the knockdown effect of FOXO1 siRNA was performed by real-time PCR analysis. Changes in cell viability were assessed using cell counting kit-8 (CCK-8) assays. In addition, we verified the effect of FOXO1 on the PCa cell cycle using a cell cycle assay. Results. Herein, we found that FOXO1 was significantly downregulated in PCa tissues and was significantly associated with Gleasons score, age, biochemical recurrence (BCR), and lymph node (LN) status, while FOXO1 expression was independent of pathological staging and preoperative PSA levels. The Kaplan-Meier survival analysis showed that PCA patients with high FOXO1 expression were less likely to develop BCR compared with patients with low FOXO1 expression. In terms of function, FOXO1 inhibition significantly promoted the proliferation and cell cycle progression of PCa cells. Conclusions. In summary, our study suggests that FOXO1 may be one of the prognostic factors that describe the risk of PCa for BCR. These results suggest that FOXO1 may be a therapeutic target for PCa.


  • Open Access

    Fusion imaging-guided radiofrequency ablation for residual hepatocellular carcinoma invisible on ultrasound after transcatheter arterial chemoembolization

    by Jiong-Hui Gu, Qi-Yu Zhao, Chang He, Zheng-Du Ye, Min Xu, Tian-An Jiang

    This study aimed to investigate the technical efficiency and therapeutic response of fusion imaging (considered as virtual navigation) between contrast-enhanced ultrasound (CEUS) and contrast-enhan...


  • Open Access

    Primary rhabdomyosarcoma of tunica vaginalis misdiagnosing as hydrocele: A case report and literature review

    by Fan Yang, Jiawen Wu, Xuwei Lu, Zhuifeng Guo, Liang Qing, Chang He

    Primary rhabdomyosarcoma of tunica vaginalis is very rare. We report a case of a 15‐year‐old man presenting as hydrocele. Pre‐operatively, no masses were detected by ultrasonography. Hydrocelectomy was performed. At surgery, a 0.8 cm polypoid nodule and diffusely thickened tunica were found. Pathologic examination finally revealed rhabdomyosarcoma. A PET‐CT was then performed and indicated scrotal implantation metastasis. The patient underwent radical inguinal orchiectomy and was treated with chemotherapy and radiotherapy after surgery. At 12 months of follow‐up, he remained disease‐free.